US · Healthcare · Medical Instruments & Supplies
EPS came in at 1.09 against a street estimate of 0.85 — a beat of 28.2%.
Analysts rate Merit Medical Systems Inc a buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $101.45.
CONFIDENT Merit delivered 9% organic growth, strongest in 3 years, with operating margins up 142 bps to 22.6%. Raised full-year EPS and revenue guidance. Three acquisitions (View Point, Biolife, C2 CryoBalloon) tracking ahead of plan. Q2 2026 U.S. growth significantly outpaced international; China tracking in line with expectations despite VBP headwinds. Analysts pressed on Q2 beat sustainability vs seasonality, tariff uncertainty, and portfolio pruning in new 3-year plan. Management emphasized Q3 summer seasonality is normal, tariff volatility justifies guidance range width, and detailed strategic review underway but committed to finishing CGI first. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 14.80% |
| Vanguard Portfolio Management, LLC | 5.90% |
| Vanguard Capital Management, LLC | 4.45% |
| State Street Corp | 3.95% |
| Fuller & Thaler Asset Management Inc | 3.54% |
| Conestoga Capital Advisors, LLC | 3.32% |
| Geode Capital Management, LLC | 2.53% |
| Dimensional Fund Advisors, Inc. | 2.44% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 MERIT MEDICAL SYSTEMS, INC. – FORM 8-K SUMMARY August 14, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Merit Medical Systems is a medical device compan | 2026-08-20 |
| Quarterly report · Q2 2026 MERIT MEDICAL SYSTEMS INC – Q2 2026 SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $418.8 million (up 9.5% vs Q2 2025: $382.5 million) • H1 2026 Net | 2026-07-30 |
| Results announced · Q3 2026 MERIT MEDICAL SYSTEMS, INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $418.8 million, up 10% reported, up 9% constant currency | 2026-07-30 |
| Board / officer change · Q2 2026 MERIT MEDICAL SYSTEMS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Shareholder Meeting held May 13, 2026 • 59,648,292 total shares entitled to | 2026-05-19 |
| Quarterly report · Q1 2026 MERIT MEDICAL SYSTEMS INC. - Q1 2026 SUMMARY --- HEADLINE NUMBERS • Net sales: $381,877 thousand (Q1 2026) vs. $355,351 thousand (Q1 2025) — increa | 2026-04-30 |
| Results announced · Q2 2026 MERIT MEDICAL SYSTEMS, INC. – Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 revenue: $381.9 million, up 7% reported; up 5% constant currency; | 2026-04-30 |
| Proxy statement · Q2 2026 MERIT MEDICAL SYSTEMS INC — PROXY STATEMENT SUMMARY --- CEO COMPENSATION • Martha G. Aronson (current CEO, appointed 2025): Total compensation figu | 2026-03-31 |
| Annual report FY2025 MERIT MEDICAL SYSTEMS INC — ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Market capitalization: $5.4 billion (as of June 30, 2025) • Outstanding shares: | 2026-02-24 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquired View Point Medical for approximately $140 million in merger transaction Merit Medical Systems acquired View Point Medical, Inc. for approximately $140 million, gaining View Point's OneMark Detection Imaging System, OneMark Tissue Markers, and related assets. The | 2026-04-01 |
| Closed acquisition of C2 CryoBalloon device and related technology Merit Medical Systems completed its acquisition of the C2 CryoBalloon device and related technology from Pentax of America on November 3, 2025. The deal was announced on October 17, 2025, an | 2025-11-03 |
| Signed definitive agreement to acquire C2 CryoBalloon device and related technology Merit Medical Systems announced on October 15, 2025, that it has signed a definitive agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America for $22 mill | 2025-10-17 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Merit Medical Systems Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.